Apixaban in Patients With Left Ventricular Thrombus

• Status: Completed
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Saud Al Babtain Cardiac Center
• Treatments: Apixaban; Warfarin

Criteria

Inclusion Criteria:

All the following criteria must be fulfilled:

• Ages between 18 and 80 years,

• History of anterior wall MI, either acute (within a week) or recent (within a month)

• Evident left ventricular thrombus (LVT) by transthoracic echocardiography,

• Naïve to oral anticoagulants (OAC)

• stable to start OAC

Exclusion Criteria:

• Other indications for OAC,

• Patients with contraindications for OAC,

• Right ventricular thrombus or atrial thrombus,

• History of confirmed stroke or other systemic embolization within the previous six months,

• High bleeding risk,

• Severe renal impairment,

• Patients with expected difficulties to follow the INR strictly.